Avidity Biosciences, Inc.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS5
PHASE 3 / 2-33
RECRUITING2
READOUTS ≤12 MONTHS1
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| EXPLORE44OLE NCT06244082 |
P2 | Active, not recruiting | DMD; Duchenne Muscular Dystrophy | 39 | 2027-04-30 (+16 mo) |
| FORTITUDE-3 NCT07038200 |
P3 | Recruiting | Facioscapulohumeral Muscular Dystrophy; FSHD | 200 | 2028-05 |
| SAFARI44 NCT07587242 |
P3 | Recruiting | Muscular Dystrophies; Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy) | 70 | 2029-05 |
| FORTITUDE-OLE NCT06547216 |
P2 | Active, not recruiting | FSHD; FSHD1 | 84 | 2030-04 (+24 mo) |
| HARBOR-OLE NCT07008469 |
P3 | Enrolling by invitation | Myotonic Dystrophy Type 1; DM1 | 199 | 2030-10 (+2 mo) |